

# Isocapnic Hyperventilation Increases Carbon Monoxide Elimination and Oxygen Delivery

THOMAS C. KRECK, ERIN D. SHADE, WAYNE J. E. LAMM, STEVEN E. MCKINNEY, and MICHAEL P. HLASTALA

Departments of Medicine, Physiology, and Biophysics, University of Washington, Seattle, Washington

Hyperventilation with mixtures of O<sub>2</sub> and CO<sub>2</sub> has long been known to enhance carbon monoxide (CO) elimination at low HbCO levels in animals and humans. The effect of this therapy on oxygen delivery (Do<sub>2</sub>) has not been studied. Isocapnic hyperventilation utilizing mechanical ventilation may decrease cardiac output and therefore decrease Do<sub>2</sub> while increasing CO elimination. We studied the effects of isocapnic hyperventilation on five adult mechanically ventilated sheep exposed to multiple episodes of severe CO poisoning. Five ventilatory patterns were studied: baseline minute ventilation (RR · V<sub>T</sub>), twice (2 · RR) and four times (4 · RR) baseline respiratory rate, and twice (2 · V<sub>T</sub>) and four times (4 · V<sub>T</sub>) baseline tidal volume. The mean carboxyhemoglobin (HbCO) washout half-time (t<sub>1/2</sub>) was 14.3 ± 1.6 min for RR · V<sub>T</sub>, decreasing to 9.5 ± 0.9 min for 2 · RR, 8.0 ± 0.5 min for 2 · V<sub>T</sub>, 6.2 ± 0.5 min for 4 · RR, and 5.2 ± 0.5 min for 4 · V<sub>T</sub>. Do<sub>2</sub> was increased during hyperventilation compared with baseline ventilation for 2 · V<sub>T</sub>, 4 · RR, and 4 · V<sub>T</sub> ventilatory patterns. Isocapnic hyperventilation, in our animal model, did not alter arterial or pulmonary blood pressures, arterial pH, or cardiac output. Isocapnic hyperventilation is a promising therapy for CO poisoning.

Isocapnic hyperventilation has been proposed as a possible “new” therapy for carbon monoxide (CO) poisoning (1). Early studies of hyperventilation for CO poisoning used unassisted ventilation with a fixed fraction of carbon dioxide (CO<sub>2</sub>) in oxygen (O<sub>2</sub>) (2–4), whereas Fisher and coworkers more recently used a passive apparatus that introduced CO<sub>2</sub> at rates proportional to minute ventilation (V<sub>E</sub>) (5). The benefit of unassisted isocapnic hyperventilation, as practiced before the onset of mechanical ventilation, was limited because increased CO elimination rates depend on spontaneous or voluntary increases in V<sub>E</sub>. Takeuchi and coworkers have proven that 90 min of spontaneous hyperventilation, 2 to 6 times baseline V<sub>E</sub>, is possible in conscious volunteers with low levels of carboxyhemoglobin (HbCO) (6), but these subjects may not adequately model the typical CO-poisoned patient. As predicted by mathematical models (7–10) and confirmed in dogs (1) and humans (6), large increases in V<sub>E</sub> are required to significantly increase rates of CO elimination. An optimal level of hyperventilation may not be spontaneously sustainable in clinical practice because the time required to decrease HbCO levels to 25% of their initial value is up to 160 min for normobaric O<sub>2</sub> (NBO) at baseline V<sub>E</sub> (11).

Hyperventilation therapy using mechanical ventilatory support is a viable option but cardiac output may be compromised by increased intrathoracic pressure and reduced venous blood return to the heart. If this were the case, O<sub>2</sub> delivery to tissue (Do<sub>2</sub>) would decline acutely during therapy when tissue Po<sub>2</sub> is at low levels, potentially worsening the clinical condition of the patients. Fisher and coworkers demonstrated a dramatic in-

crease in CO elimination in dogs mechanically ventilated with a tidal volume (V<sub>T</sub>) of 50 ml · kg<sup>-1</sup> when isocapnic hyperventilation was compared with normal ventilation with NBO or room air (RA) ventilation. Because the order of each treatment was fixed and each therapy arm was performed at different mean HbCO levels (51% for RA, 25% for NBO, and 6% for hyperventilation), this study was not able to address the issue of Do<sub>2</sub> during hyperventilation at high HbCO levels.

We used an animal model of multiple severe CO poisonings to assess the effect of isocapnic hyperventilation on CO elimination and Do<sub>2</sub> at high HbCO levels. Because large increases in V<sub>T</sub> may result in increased alveolar ventilation (V<sub>A</sub>) but decreased cardiac output compared with increases in respiratory rate (RR), we also examined the effect of respiratory pattern on CO elimination and Do<sub>2</sub>.

## METHODS

### Animal Model

This study was approved by the University of Washington (Seattle, WA) Institutional Animal Care and Use Committee and the National Institutes of Health guidelines for animal use and care were followed throughout. Five adult sheep (27.5–36 kg) of either sex were studied. The animals were premedicated by intramuscular injection of xylazine (1.0 mg · kg<sup>-1</sup>), anesthetized by intravenous administration of thiopental sodium (20 mg · kg<sup>-1</sup>), and intubated. Anesthesia was maintained throughout the study, using a constant intravenous infusion of thiopental sodium, titrated to suppress hemodynamic and motor responses to noxious stimuli. The animals were initially ventilated with a piston animal ventilator (Harvard Apparatus, Holliston, MA) with a V<sub>T</sub> from 10 to 15 ml · kg<sup>-1</sup>, zero positive end-expiratory pressure (PEEP), and a respiratory rate (RR) set to maintain the arterial Pco<sub>2</sub> between 35 and 40 mm Hg. A Swan-Ganz pulmonary artery catheter was placed via the right external jugular vein and arterial and venous catheters were placed in the left groin. The animal was then placed in the prone posture for the remainder of the study. Animals were killed after completion of the study, using a concentrated pentobarbital injection. Data collected include hemoglobin (Hb) concentration, heart rate (HR), arterial pressure (Pa), pulmonary arterial pressure (Ppa), pulmonary capillary wedge pressure (Pcw), thermodilution cardiac output, airway pressures, inspired and exhaled CO<sub>2</sub> concentrations, arterial and mixed venous blood gases (pH, Po<sub>2</sub>, Pco<sub>2</sub>), and arterial HbCO levels. All exhaust gas from the ventilators was scavenged and released outside the building with ambient air tested continuously for CO.

### Treatment Trials

Each animal was exposed to six cycles of CO poisoning and treatment. Poisoning was accomplished by inhalation of 0.6% CO gas in air for 20 to 30 min, delivered via ventilator, until arterial [HbCO] reached 65 to 75%. Ventilation treatment trials were performed with a Servo 900C ventilator (Seimens-Eléma, Solna, Sweden) at varying V<sub>T</sub>, RR, and F<sub>I,CO2</sub> (fraction of inspired carbon dioxide; balance O<sub>2</sub>). After the first poisoning, the animals were ventilated with the Servo ventilator at the baseline ventilatory pattern (RR · V<sub>T</sub>) with an RR of 10 breaths · min<sup>-1</sup> and a V<sub>T</sub> adjusted to maintain Pco<sub>2</sub> between 35 and 40 mm Hg. The initial HbCO measurement and Do<sub>2</sub> calculation for each trial were made immediately after switchover to CO<sub>2</sub>:O<sub>2</sub> ventilation and continued every 5 min until [HbCO] fell below 20%, at which time poisoning was reinstated. The remaining five trials, performed in varied order, were used to test different ventilatory treatments and

(Received in original form March 8, 2000 and in revised form October 11, 2000)

Supported by National Institutes of Health grants HL-09811 and HL-12174.

Correspondence and requests for reprints should be addressed to Thomas C. Kreck, M.D., Box 356522, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195-6522. E-mail: kreck@u.washington.edu  
Am J Respir Crit Care Med Vol 163, pp 458–462, 2001  
Internet address: www.atsjournals.org

**TABLE 1**  
DESCRIPTION OF THE FIVE TREATMENTS  
FOR CO POISONING STUDIES

Trial	Respiratory Rate	Tidal Volume	$\dot{V}_E$	$\dot{V}_A$
RR · V <sub>T</sub>	Baseline	Baseline	Baseline	Baseline
2 · RR	2 · Baseline	Baseline	2 · Baseline	2 · Baseline
2 · V <sub>T</sub>	Baseline	2 · Baseline	2 · Baseline	2.5 · Baseline
4 · RR	4 · Baseline	Baseline	4 · Baseline	4 · Baseline
4 · V <sub>T</sub>	Baseline	4 · Baseline	4 · Baseline	5.6 · Baseline

Definition of abbreviations: RR · V<sub>T</sub> = baseline trial; RR = baseline respiratory rate; V<sub>T</sub> = baseline tidal volume;  $\dot{V}_E$  = minute ventilation;  $\dot{V}_A$  = alveolar ventilation (estimated).


are listed in Table 1. For all hyperventilation trials, the amount of inspired CO<sub>2</sub> was adjusted to maintain arterial PCO<sub>2</sub> between 30 and 40 mm Hg.

### Data Analysis


CO elimination rates were compared across treatment trials in each animal, allowing each sheep to serve as its own control, increasing the power of the study and limiting the number of animals required. The HbCO washout half-time ( $t_{1/2}$ ) of each of the therapies was determined graphically for each animal studied by plotting HbCO levels over time for each treatment trial. Do<sub>2</sub> (ml O<sub>2</sub> · min<sup>-1</sup> · kg<sup>-1</sup>) is the product of blood O<sub>2</sub> content and the cardiac index (CI). O<sub>2</sub> saturation (%) = 100% - HbCO (%), because F<sub>I</sub>O<sub>2</sub> remained above 550 mm Hg throughout treatment and all heme units were saturated with O<sub>2</sub> or CO. All comparisons used analysis of variance (ANOVA), with  $p < 0.05$  indicating significance. Because larger values of HbCO and Do<sub>2</sub> show more variability than smaller values, statistical tests that assume constant variance will not yield accurate  $p$  values. Log(HbCO) and log(Do<sub>2</sub>) showed similar variability across their ranges of values; therefore, statistical tests were performed with the logarithms of these variables. To avoid multiple comparison effects, the Fisher protected least significant difference was used. The first trial for all animals, always performed at normal ventilation, functioned only to "load" extravascular tissues with CO and was not included in any of the analyses.

### RESULTS

Increases in  $\dot{V}_E$  are associated with decreasing HbCO  $t_{1/2}$  (Figure 1). In the five sheep studied, the mean HbCO  $t_{1/2}$  was  $14.3 \pm$




**Figure 1.** Mean HbCO  $t_{1/2}$  for various ventilatory patterns. The HbCO  $t_{1/2}$  for each ventilatory pattern is significantly different from the  $t_{1/2}$  of all other ventilatory patterns ( $p < 0.05$ ). Vertical bars indicate 1 standard deviation (SD). See Table 1 for description of ventilatory patterns.



**Figure 2.** HbCO  $t_{1/2}$  versus alveolar ventilation ( $\dot{V}_A$ ).  $\dot{V}_A$  is calculated using measured  $\dot{V}_E$  and an estimated fixed deadspace fraction equal to 35% of baseline V<sub>T</sub>. HbCO half-lives for trials RR · V<sub>T</sub>, 2 · RR, 2 · V<sub>T</sub>, 4 · RR, and 4 · V<sub>T</sub> for all sheep are plotted. The fitted curve is represented by HbCO  $t_{1/2} = \alpha + \beta \exp(\gamma \dot{V}_A)$ , where  $\alpha = 5.20 (\pm 0.33)$ ,  $\beta = 21.2 (\pm 1.84)$ , and  $\gamma = -0.279 (\pm 0.031)$ . See Table 1 for a description of ventilatory patterns.

1.6 min for baseline ventilation (RR · V<sub>T</sub>),  $9.5 \pm 0.9$  min when RR was doubled (2 · RR),  $8.0 \pm 0.5$  min when V<sub>T</sub> was doubled (2 · V<sub>T</sub>),  $6.2 \pm 0.5$  min when RR was quadrupled (4 · RR), and  $5.2 \pm 0.5$  min when V<sub>T</sub> was quadrupled (4 · V<sub>T</sub>). The HbCO half-lives for each ventilatory pattern are significantly different from the HbCO half-lives for all other ventilatory patterns ( $p < 0.05$ ).

$\dot{V}_A$  can be estimated for each level of  $\dot{V}_E$  by assuming a fixed deadspace (V<sub>ds</sub>) equal to 35% of baseline V<sub>T</sub> (unpublished data for normal prone sheep). Figure 2 demonstrates the relationship between HbCO  $t_{1/2}$  and  $\dot{V}_A$ , described by an exponential function: HbCO  $t_{1/2} = \alpha + \beta \exp(\gamma \dot{V}_A)$ , where:  $\alpha = 5.20 (\pm 0.33)$ ,  $\beta = 21.2 (\pm 1.84)$ , and  $\gamma = -0.279 (\pm 0.031)$ . This exponential function fit the data better ( $r^2 = 0.961$ ) than an



**Figure 3.** Oxygen delivery during treatment with various levels of isocapnic ventilation. Differences are noted when  $p < 0.05$ : \*RR · V<sub>T</sub> significantly different from 4 · V<sub>T</sub>; <sup>#</sup>RR · V<sub>T</sub> significantly different from 4 · RR; <sup>#</sup>RR · V<sub>T</sub> significantly different from 2 · V<sub>T</sub>. Open triangles, RR · V<sub>T</sub>; open circles, 2 · RR; open squares, 2 · V<sub>T</sub>; open diamonds, 4 · RR; open inverted triangles, 4 · V<sub>T</sub>. Vertical bars indicate 1 standard deviation (SD). See Table 1 for a description of ventilatory patterns.

TABLE 2  
HEMODYNAMIC AND GAS EXCHANGE PARAMETERS DURING FIVE  
TREATMENT TRIALS USING DIFFERENT VENTILATORY PATTERNS\*

Parameter	RR · V <sub>T</sub>	2 · RR	2 · V <sub>T</sub>	4 · RR	4 · V <sub>T</sub>
Pa (mean), mm Hg	86 ± 20	93 ± 10	85 ± 13	87 ± 6	93 ± 14
Ppa (mean), mm Hg	18 ± 4	17 ± 5	19 ± 2	18 ± 5	18 ± 2
Pcw, mm Hg	10 ± 3	9 ± 2	11 ± 2	10 ± 1	10 ± 2
HR, min <sup>-1</sup>	111 ± 7	118 ± 10	119 ± 13	125 ± 18 <sup>†</sup>	116 ± 13
CI, ml · min <sup>-1</sup> · kg <sup>-1</sup>	146 ± 30	151 ± 40	154 ± 25	153 ± 31	137 ± 27
pH (arterial)	7.40 ± 0.05	7.43 ± 0.04	7.40 ± 0.03	7.40 ± 0.02	7.44 ± 0.03
Pa <sub>O<sub>2</sub></sub> , mm Hg	588 ± 21	606 ± 35	603 ± 40	576 ± 61 <sup>‡§</sup>	615 ± 29 <sup>†  </sup>
Pa <sub>CO<sub>2</sub></sub> , mm Hg	37.3 ± 2.7	35.5 ± 2.6	33.9 ± 1.9 <sup>†</sup>	34.2 ± 2.7 <sup>†</sup>	32.3 ± 2.7 <sup>†‡</sup>

Definition of abbreviations: CI = cardiac index; HR = heart rate; RR · V<sub>T</sub> = baseline trial; Pa = systemic arterial blood pressure; Pa<sub>CO<sub>2</sub></sub> = arterial pressure of carbon dioxide; Pa<sub>O<sub>2</sub></sub> = arterial pressure of oxygen; RR = baseline respiratory rate; V<sub>T</sub> = baseline tidal volume; Ppa = pulmonary arterial pressure; Pcw = pulmonary capillary wedge pressure.

\* mean values ± interanimal SD.

<sup>†</sup> p < 0.05 compared with RR · V<sub>T</sub>.

<sup>‡</sup> p < 0.05 compared with 2 · RR.

<sup>§</sup> p < 0.05 compared with 2 · V<sub>T</sub>.

<sup>||</sup> p < 0.05 compared with 4 · RR.

exponential function with an asymptote at zero ( $r^2 = 0.860$ ) or a quadratic polynomial ( $r^2 = 0.925$ ).

Do<sub>2</sub> was increased during treatment with all patterns of hyperventilation compared with baseline ventilation (Figure 3). The difference in Do<sub>2</sub> reached significance for 2 · V<sub>T</sub>, 4 · RR, and 4 · V<sub>T</sub> groups compared with RR · V<sub>T</sub> at 10 and 15 min.

Hemodynamic and gas exchange parameters for all five patterns of ventilation averaged over the duration of each treatment period in all five animals are listed in Table 2. Mean Pa, mean Ppa, Pcw, CI, and arterial pH were not different ( $p > 0.05$ ) across all ventilation patterns. Arterial Pco<sub>2</sub> was less for the 2 · V<sub>T</sub>, 4 · RR, and 4 · V<sub>T</sub> groups than for the RR · V<sub>T</sub> group ( $p < 0.05$ ). The few differences in HR and arterial Po<sub>2</sub> between ventilatory patterns that reached significance are noted in Table 2.

## DISCUSSION

Our study adds to the findings of Fisher and colleagues and Takeuchi and colleagues, that isocapnic hyperventilation increases the rate of CO elimination. Our study differs from previous work in four areas. (1) We used a multiple poisoning model, with each animal subject exposed to all treatment permutations in varied order, greatly enhancing the statistical power of the study. The multiple poisoning model developed in our laboratory has been shown to be hemodynamically stable and yields highly reproducible HbCO t<sub>1/2</sub> for up to seven repeat poisonings (12, 13); (2) we studied the effects of isocapnic hyperventilation at clinically relevant HbCO levels. Takeuchi and coworkers used low HbCO levels in human volunteers, with a peak [HbCO] of 12%. Fisher and coworkers studied dogs with severe CO poisoning, but each treatment was performed at different HbCO levels, the order of the treatments was not varied, and isocapnic hyperventilation was performed on each animal at the lowest HbCO levels (mean [HbCO] approximately 11%). While HbCO t<sub>1/2</sub> is relatively independent of HbCO levels, other clinically relevant variables may depend heavily on HbCO levels. For example, Do<sub>2</sub> measurements are highly related to HbCO levels. Do<sub>2</sub> will be higher when HbCO is lower, particularly under high F<sub>I</sub>O<sub>2</sub> conditions, because heme sites not occupied by CO would be occupied by O<sub>2</sub>. In addition, tissue oxygen debt and acidosis, CO<sub>2</sub> production, myocardial contractility, and the rate of venous blood return may also vary significantly with HbCO levels; (3) we measured Do<sub>2</sub> during all treatment trials, whereas previous

studies had not; and (4) we studied the effects of RR and V<sub>T</sub> increases on HbCO t<sub>1/2</sub> and Do<sub>2</sub> by varying RR and V<sub>T</sub> independently over a 4-fold range.

Isocapnic hyperventilation increased CO elimination in a dose-dependent manner, with a 4-fold increase in V<sub>T</sub> resulting in a 2.75-fold increase in the CO elimination rate (Figure 1). This finding is consistent with the findings of increased CO elimination with isocapnic hyperventilation by Fisher and colleagues in dogs (2.33-fold) and by Takeuchi and colleagues in human volunteers (2.52-fold), using comparable levels of hyperventilation. A similar relationship between hyperventilation and CO elimination is predicted by the CFK model of CO kinetics described by Coburn, Forster, and Kane (7).

Ventilatory pattern affects CO elimination. A higher V<sub>T</sub> and lower RR results in faster CO elimination than a higher RR and lower V<sub>T</sub> at the same overall  $\dot{V}_E$  (Figure 1). Presumably, high V<sub>T</sub> ventilation results in a lower deadspace fraction (V<sub>d</sub>/V<sub>T</sub>) and higher  $\dot{V}_A$  than low V<sub>T</sub> ventilation. The relationship between HbCO t<sub>1/2</sub> and  $\dot{V}_A$  (estimated) suggests an upper limit of effective ventilation because HbCO t<sub>1/2</sub> does not change significantly when  $\dot{V}_A$  is increased from 15 to 20 L/min (Figure 2). The relationship between CO elimination and  $\dot{V}_A$  in our study, diminishing effect at higher  $\dot{V}_A$ , is consistent with the CFK mathematical model, the findings of Takeuchi and coworkers in humans, and a diffusion limitation to CO transport in the lung.

Do<sub>2</sub> is likely to be at least as relevant an end point as HbCO t<sub>1/2</sub> because a therapy that results in a decreased Do<sub>2</sub> while increasing CO elimination could possibly result in greater morbidity than more conservative treatment. We observed a dose-dependent increase in Do<sub>2</sub> during isocapnic hyperventilation in our prone sheep model; for increases in  $\dot{V}_E$  we demonstrate increases in Do<sub>2</sub> (Figure 3). Cardiac index was not attenuated by any of the patterns of hyperventilation in this study, even with V<sub>T</sub> as high as 60 ml · kg<sup>-1</sup> (Table 2). HbCO levels fell faster during the hyperventilation trials, resulting in increased Do<sub>2</sub> compared with control.

Isocapnic hyperventilation did not cause overt changes in hemodynamics, gas exchange, or lung mechanics. Mean Pa did not decrease with hyperventilation. Likewise, Ppa and Pcw were not altered. Arterial Po<sub>2</sub> increased during three of the four hyperventilation patterns even under conditions of "high stretch ventilation" (V<sub>T</sub> = 60 ml · kg<sup>-1</sup>) and baseline Po<sub>2</sub> values were unchanged between trials, even after multiple exposures to high V<sub>T</sub> ventilation. Airway pressures and arterial Pco<sub>2</sub> re-

turned to normal after each treatment trial. It should be noted that the lack of significant hemodynamic or pulmonary alterations during hyperventilation is demonstrated in prone sheep; the hemodynamic effects of positive-pressure hyperventilation in CO-poisoned supine humans remain unknown. The size of  $V_T$  in this and a previous animal study (dog) of isocapnic hyperventilation for CO poisoning is far greater than what is currently recommended for patients with acute respiratory distress syndrome (ARDS) (14). However, we are not aware of any studies that demonstrate lung damage from large  $\dot{V}_E$  or  $V_T$  ventilation in normal lungs. In fact, an abstract demonstrated no lung damage in burn patients ventilated at 2- to 10-fold baseline  $\dot{V}_E$  (15). In addition, sustained spontaneous isocapnic hyperventilation in normal human volunteers was well tolerated (6). Future studies of human victims of CO poisoning will be needed to address the effect of mechanically induced hyperventilation on lung function.

Although the  $2 \cdot V_T$ ,  $4 \cdot RR$ , and  $4 \cdot V_T$  trials had significantly lower mean arterial  $P_{CO_2}$  than the baseline ventilation trial, the  $P_{CO_2}$  was not significantly different between any of the hyperventilation trials. The difference in  $P_{CO_2}$  between the highest and lowest  $\dot{V}_E$  was only 5 mm Hg and not clinically significant. In this study,  $F_{ICO_2}$  was adjusted manually for each of the five levels of ventilation. It is possible that a device such as the one used by Fisher and coworkers could have been used to keep  $P_{CO_2}$  within a tighter range.

We used a sheep model of severe CO poisoning for several reasons. First, sheep have been used by multiple investigators in the past to study physiologic effects of CO and CO elimination under a variety of conditions, and the kinetics of CO association/dissociation from sheep Hb have been well studied (16–21). Second, because sheep Hb has a lower affinity (M) for CO (140–150) than most other species ( $\sim 250$ ) they lend themselves more readily to the study of multiple repeat poisoning (21); a similar study in dogs would have required nearly 24 h. Finally, previous studies in our laboratory have observed stable hemodynamic variables and gas exchange parameters in sheep with multiple poisonings (12, 13), findings confirmed in this study. Because the treatment effect of hyperventilation is normalized to tidal breathing of pure  $O_2$  in each animal we believe the fractional improvement in CO elimination rates would apply across species. This appears to be the case because previous studies of hyperventilation in dogs and humans report similar results (1, 6).

Hyperventilation with exogenous  $CO_2$  and  $O_2$  may result in hypocapnia or hypercapnia if  $\dot{V}_E$  and  $F_{ICO_2}$  are not well matched. Hypocapnia is a potentially dangerous complication resulting in lower tissue  $P_{O_2}$  due to further increase in the affinity of Hb for  $O_2$  (in addition to the increased affinity caused by CO) as well as cerebral vasoconstriction (22). Hypercapnia, on the other hand, is associated with mild increases in cardiac output and systolic Pa in critically ill patients (23), increases in  $DO_2$  in animals (24), and a right shift in the oxyhemoglobin dissociation curve, which would counter the CO-induced increase in Hb- $O_2$  affinity. Hyperventilation with excessive levels of  $CO_2$  may be safer than hyperventilation without adequate levels of exogenous  $CO_2$ . Considering the risks of hypocapnia and the decreasing effect of hyperventilation for CO removal at very high  $\dot{V}_E$ , it may be advisable in clinical practice to use a fixed  $F_{ICO_2}$  gas source such as Carbogen (5%  $CO_2$  + 95%  $O_2$ ) and an initial recommended  $\dot{V}_E$  (perhaps 20 L/min). If isocapnic hyperventilation for CO poisoning is attempted in humans, whether a fixed or variable source of  $CO_2$  is used, care must be taken to ensure that eucapnea is maintained. Because mild hypercapnia does not appear to be detrimental a fixed  $F_{ICO_2}$  gas source may be safer than a mecha-

nism with varying  $F_{ICO_2}$  and may be more quickly and easily implemented.

While the increases in CO elimination rates during hyperbaric oxygen therapy (HBO) are incontrovertible, the clinical benefit of HBO remains uncertain. HBO (at 3 ATA [atmosphere absolute]) increases the rate of CO elimination 3.5-fold compared with NBO (8), but a prospective randomized sham study of HBO versus NBO demonstrated no neurological or survival benefit of HBO (25). In addition, the observation that HbCO levels at presentation are poorly correlated with clinical manifestations suggests that the rate of CO elimination is not the only factor associated with clinical effect (26–29). The lack of consistently observed clinical benefit of HBO may be due solely to delays in initiating therapy (30). Therefore hyperventilation therapy, which eliminates CO nearly as quickly as HBO and is more readily accessible, could have a significant clinical benefit.

In conclusion, we have demonstrated up to a 2.75-fold increase in CO elimination and increases in  $DO_2$  with isocapnic ventilation in an animal model of severe CO poisoning. These findings, the findings of others in animals and human volunteers, and the potentially universal access of isocapnic hyperventilation warrant further study of this therapy in CO-poisoned patients.

## References

1. Fisher JA, Rucker J, Sommer LZ, Vesely A, Lavine E, Greenwald Y, Volgyesi G, Fedorko L, Iscoe S. Isocapnic hyperpnea accelerates carbon monoxide elimination. *Am J Respir Crit Care Med* 1999;159:1289–1292.
2. Henderson Y, Haggard HW. The treatment of carbon monoxide asphyxia by means of oxygen and  $CO_2$  inhalation. *JAMA* 1922;79:1137–1145.
3. Stadie W, Martin KA. The elimination of carbon monoxide from the blood. *J Clin Invest* 1925;2:77–91.
4. Killick EM, Marchant JV. Resuscitation of dogs from severe acute carbon monoxide poisoning. *J Physiol (Lond)* 1959;147:274–298.
5. Sommer LZ, Iscoe S, Robicsek A, Kruger J, Silverman J, Rucker J, Dickstein J, Volgyesi GA, Fisher JA. A simple breathing circuit minimizing changes in alveolar ventilation during hyperpnoea. *Eur Respir J* 1998;12:698–701.
6. Takeuchi A, Vesely A, Rucker J, Sommer LZ, Tesler J, Lavine E, Slutsky AS, Maleck WH, Volgyesi G, Fedorko L, Iscoe S, Fisher JA. A simple “new” method to accelerate clearance of carbon monoxide. *Am J Respir Crit Care Med* 2000;161:1816–1819.
7. Coburn RF, Forster RE, Kane PB. Considerations of the physiological variables that determine the blood carboxyhemoglobin concentration in man. *J Clin Invest* 1965;44:1899–1910.
8. Peterson JE, Stewart RD. Absorption and elimination of carbon monoxide by inactive young men. *Arch Environ Health* 1970;21:165–171.
9. Hauck H. Parameters influencing carbon monoxide kinetics. *Exp Pathol* 1989;37:170–176.
10. Selvakumar S, Sharan M, Singh MP. A mathematical model for the elimination of carbon monoxide in humans. *J Theor Biol* 1993;162:321–336.
11. Pace N, Strajman E, Walker EL. Acceleration of carbon monoxide elimination in man by high pressure oxygen. *Science* 1950;111:652–654.
12. Kreck T, Cuignet O, Shade E, Hlastala M. Extracorporeal gas exchange for severe carbon monoxide poisoning [abstract]. *Ann Biomed Eng* 1997;25:516.
13. Cuignet O, Kreck T, Souders J, Polissar N, Hlastala H, Spiess B. Perfluorocarbon emulsions do not enhance carbon monoxide elimination in a sheep model of acute carbon monoxide poisoning [abstract]. *Anesthesiology* 1998;89:A403.
14. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network [see comments]. *N Engl J Med* 2000;342:1301–1308.
15. Morris AH, Spitzer KW. Sustained 10-fold increases in minute ventilation in burn patients do not damage the lung [abstract]. *Am J Respir Crit Care Med* 2000;161:A722.
16. Baker VV, Egley CC, Cefalo RC, Proctor H. The cardiorespiratory effects of perfluorochemicals on acute carbon monoxide poisoning in the pregnant ewe. *Am J Obstet Gynecol* 1986;155:1128–1134.

17. Dodgson SJ, Holland RA. The reaction kinetics of four sheep haemoglobins with identical alpha-chains. *Respir Physiol* 1983;53:31–45.
18. Gray RD. Quaternary structure of partially liganded intermediates of sheep carbon monoxide hemoglobin at alkaline pH. *J Biol Chem* 1975;250:790–792.
19. Longo LD, Hill EP. Carbon monoxide uptake and elimination in fetal and maternal sheep. *Am J Physiol* 1977;232:H324–H330.
20. Sharan M, Popel AS. Algorithm for computing oxygen dissociation curve with pH,  $P_{CO_2}$ , and CO in sheep blood. *J Biomed Eng* 1989;11:48–52.
21. Werlen C, Py P, Haab P. Alveolar-arterial equilibration in the lung of sheep. *Respir Physiol* 1984;55:205–221.
22. Fortune JB, Bock D, Kupinski AM, Stratton HH, Shah DM, Feustel PJ. Human cerebrovascular response to oxygen and carbon dioxide as determined by internal carotid artery duplex scanning. *J Trauma* 1992;32:618–627; 627–628 [discussion].
23. Capellier G, Toth JL, Walker P, Marshall J, Winton T, Demajo W. Hemodynamic effects of permissive hypercapnia [abstract]. *Am Rev Respir Dis* 1992;145:A527.
24. Torbati D, Mangino MJ, Garcia E, Estrada M, Totapally BR, Wolfsdorf J. Acute hypercapnia increases the oxygen-carrying capacity of the blood in ventilated dogs. *Crit Care Med* 1998;26:1863–1867.
25. Scheinkestel CD, Bailey M, Myles PS, Jones K, Cooper DJ, Millar IL, Tuxen DV. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. *Med J Aust* 1999;170:203–210.
26. Krantz T, Thisted B, Strom J, Sorensen MB. Acute carbon monoxide poisoning. *Acta Anaesthesiol Scand* 1988;32:278–282.
27. Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. *Arch Neurol* 1983;40:433–435.
28. Garland H, Pearce J. Neurological complications of carbon monoxide poisoning. *Q J Med* 1967;36:445–455.
29. Winter PM, Miller JN. Carbon monoxide poisoning. *JAMA* 1976;236:1502.
30. Goulon M, Barois A, Rapin M, Nouailhat F, Grosbuis S, Labrousse J. Carbon monoxide poisoning and acute anoxia due to inhalation of coal gas and hydrocarbons: 302 cases, 273 treated by hyperbaric oxygen at 2 ATA. *Ann Med Interne (Paris)* 1969;120:335–349.